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Abstract
Background: Bladder cancer is common disease with a complex etiology that is
likely due to many different genetic and environmental factors. The goal of this
study was to embrace this complexity using a bioinformatics analysis pipeline
designed to use machine learning to measure synergistic interactions between
single nucleotide polymorphisms (SNPs) in two genome-wide association studies
(GWAS) and then to assess their enrichment within functional groups defined by Gene
Ontology. The significance of the results was evaluated using permutation testing and
those results that replicated between the two GWAS data sets were reported.
Results: In the first step of our bioinformatics pipeline, we estimated the pairwise
synergistic effects of SNPs on bladder cancer risk in both GWAS data sets using
Multifactor Dimensionality Reduction (MDR) machine learning method that is designed
specifically for this purpose. Statistical significance was assessed using a 1000-fold
permutation test. Each single SNP was assigned a p-value based on its strongest
pairwise association. Each SNP was then mapped to one or more genes using a
window of 500 kb upstream and downstream from each gene boundary. This window
was chosen to capture as many regulatory variants as possible. Using Exploratory Visual
Analysis (EVA), we then carried out a gene set enrichment analysis at the gene level to
identify those genes with an overabundance of significant SNPs relative to the size of
their mapped regions. Each gene was assigned to a biological functional group defined
by Gene Ontology (GO). We next used EVA to evaluate the overabundance of
significant genes in biological functional groups. Our study yielded one GO category,
carboxy-lysase activity (GO:0016831), that was significant in analyses from both GWAS
data sets. Interestingly, only the gamma-glutamyl carboxylase (GGCX) gene from this
GO group was significant in both the detection and replication data, highlighting the
complexity of the pathway-level effects on risk. The GGCX gene is expressed in the
bladder, but has not been previously associated with bladder cancer in univariate
GWAS. However, there is some experimental evidence that carboxy-lysase activity
might play a role in cancer and that genes in this pathway should be explored as drug
targets. This study provides a genetic basis for that observation.
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Conclusions: Our machine learning analysis of genetic associations in two GWAS for
bladder cancer identified numerous associations with pairs of SNPs. Gene set enrichment
analysis found aggregation of risk-associated SNPs in genes and significant genes in GO
functional groups. This study supports a role for decarboxylase protein complexes in
bladder cancer susceptibility. Previous research has implicated decarboxylases in bladder
cancer etiology; however, the genes that we found to be significant in the detection and
replication data are not known to have direct influence on bladder cancer, suggesting
some novel hypotheses. This study highlights the need for a complex systems approach
to the genetic and genomic analysis of common diseases such as cancer.
Findings
Bladder cancer is a form of cancer that typically starts in the inner lining of the bladder,
called the urothelium, and can grow into or through other layers of tissue. It is a dis-
ease responsible for approximately 16,000 deaths per year, with particular impact in the
American male population. Bladder cancer is the fourth most common cancer in men,
and affects 1 in 26 men and 1 in 90 women [1]. According to the NHGRI-EBI catalog
of published genome-wide association studies (GWAS) [2], there are five single locus
genetic variants associated with bladder cancer at a genome-wide significance level.
Collectively, these genetic factors explain a very small proportion of the overall risk.
The goal of this study was to employ a bioinformatics approach to GWAS analysis that
considers pairwise genetic interactions among SNPs followed by gene-level and
pathway-level gene set enrichment analyses. This approach is based on the hypothesis
that evolution works to stabilize health by building highly redundant gene interaction
networks within and between pathways [3]. The result of this complex biology is that
the healthy state is resilient to the effects of single mutations. What we observe in
common diseases is the accumulation of multiple mutations within these pathways that
disrupts their stability and impairs their normal function. This dependence on multiple
mutations can be observed as epistasis or non-additive gene-gene interaction [4]. The
results of univariate GWAS are consistent with this hypothesis, as few univariate
genetic effects have been found that replicate consistently across studies. The goal of
our study is to employ a bioinformatics approach to GWAS analysis that is consistent
with the idea that some genetic effects will present themselves as genetic interactions
that aggregate in genes and pathways [5, 6].
We briefly present our three-phase analysis approach below and provide a flowchart in
Figure 1 as previously presented and applied to GWAS analysis [7, 8]. The GWAS data
used is available from the NCBI dbGaP database under accession number
phs000346.v2.p2. We used here the two largest GWAS data sets including one with sub-
jects from the U.S.A. and Finland (n = 4759; 620901 SNPs) and one from Spain (n = 2228,
1072820 SNPs). These were used as detection and replication data sets, respectively. We
analyzed only SNPs common to both data sets.
Phase I: SNP-level analysis
The goal of the first phase is to carry out a pairwise analysis of all SNPs using the
Multifactor Dimensionality Reduction (MDR) method to search for additive and
non-additive genetic associations [9, 10]. MDR is a nonparametric, genetic model-
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free machine learning method that collapses high-dimensional genetic data into a
single dimension through a process called constructive induction [10]. More infor-
mation about MDR and its implementation can be found here [11]. We exhaust-
ively evaluated all pairs of SNPs and then assessed statistical significance using a
1000-fold permutation test as described previously [11]. Each SNP was assigned
the p-value of its strongest pairwise association.
Phase II: gene-level analysis
At the gene level, we first mapped all SNPs to genes using a window of 500 kb upstream
and downstream from the gene start and stop sites in order to capture regulatory variants.
We then performed a gene set enrichment analysis to determine if there were more SNPs
with p-values at or below the 0.05 significance level in gene regions than would be
expected given their size. This was accomplished using a right-tailed Fisher’s exact test
implemented in Exploratory Visual Analysis (EVA) [12, 13]. These P-values for SNP over-
abundance were then assigned to each gene.
Phase III: pathway-level analysis
The final step was to determine whether the genes with a statistically significant over-
abundance of SNPs aggregate in functional groups defined by Gene Ontology (GO) [14]
provided by the Molecular Signatures Database (MSigDB) [15]. This analysis was per-
formed using EVA as described above. P-values from the Fisher’s exact test were assigned
to each GO category. Replication at the 0.05 significance level was assessed across the two
GWAS data sets. As discussed by Kim et al. [7], permutation testing combined with this
multistep process with replication helps address false-positives due to multiple testing.
Results and discussion
Our pathway-level gene set enrichment analysis yielded one GO category, carboxy-
lysase activity (GO:0016831), that was significant in both GWAS data sets with p-values
Fig. 1 Flowchart summarizing the three phases of our machine learning and gene set enrichment
analysis strategy
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of 0.023 and 0.043. This pathway is sometimes referred to as decarboxylase activity and
has previously been explored as a target for chemotherapy because of its role in poly-
amine metabolism that is required for tumor growth [16]. Little is known about the dir-
ect role of this pathway in bladder cancer and none of the genes from this pathway
have been implicated from the results of univariate GWAS analyses. As such, our re-
sults are novel and suggest this pathway and its genes as a new biological hypothesis
for bladder cancer genetic susceptibility. If validated, genes in this pathway could be
targets for therapy given the current focus on polyamines for chemotherapy.
There were five significant genes in the detection data set and three genes in the rep-
lication data set that are members of the carboxy-lysase GO pathway. One of these,
gamma-glutamyl carboxylase (GGCX), was significant with p-values of 0.03 and 0.04 in
the detection and replication data sets, respectively. The GGCX protein is an enzyme
that catalyzes post-translational modifications to a vitamin K-dependent protein that
functions in coagulation. Mutations in GGCX are typically associated with combined
deficiency of vitamin K-dependent clotting factors 1 and hemorrhagic disease [17].
Although there is no evidence this gene plays a role in bladder cancer, it has been asso-
ciated with prostate cancer in several GWAS [18, 19]. It is possible that genetic vari-
ation in this gene is also a risk factor for bladder cancer, but that synergistic
interactions between multiple SNPs are necessary to observe a phenotype. Importantly,
there are several drug-GGCX interactions according to The Drug Gene Interaction
Database (DGIdb) [20]. Anisindione is one such drug and, according to the NCBI
PubChem database [21], is a synthetic anticoagulant that disrupts the synthesis of
clotting factors leading to the inhibition of gamma-carboxylation of glutamic acid. The
repositioning of GGCX-related drugs for the treatment of bladder cancer is an open
question. Indeed, these drugs are often considered for anticoagulation treatment in can-
cer patients because of their beneficial effect on the tumor microenvironment [22].
It is worth noting that the branched chain keto acid dehydrogenase E1 alpha
(BCKDHA) and beta (BCKDHB) gene forms were significant in the detection and repli-
cation data, respectively. Although these two genes are on different chromosomes, their
protein products are part of the same complex that is involved in the catabolism of sev-
eral amino acids. The BCKD complex is comprised of three catalytic components, one
of them being E1, a heterotetramic branched-chain alpha-keto acid decarboxylase.
BCKDHA codes for the alpha subunit of E1, while BCKDHB codes for the beta subunit
of E1. Without this decarboxylase component, 2-oxycarboxylic acid accumulates in
blood and tissues, and causes maple syrup urine disease [23–25]. There is no known
link between the effects of the BCKD complex and bladder cancer, but univariate
GWAS have implicated BCKDHA in prostate [26] and colorectal [27] cancer.
There were several limitations of the present study that should be kept in mind when
interpreting the results. First, power to detect gene-gene interactions is always a con-
cern given the curse of dimensionality that comes with considering multilocus genotype
combinations. We addressed the power concerns by using the MDR machine learning
method and by using a liberal significance level of 0.05. We also used the two largest
GWAS data sets available through dbGaP. Despite these measures, power may still be a
limiting issue. Second, we did not correct for the correlation structure of the SNPs in
the gene regions. This was primarily due to the potential co-occurrence of interactions
and linkage disequilibrium due to selection. Consideration of correlation is more
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complicated for gene-gene interactions studies than it is for significance testing of sin-
gle SNPs using univariate methods. Third, the detection and replication GWAS data
were primarily Caucasian subjects from the U.S., Finland, and Spain. These results may
not generalize to other populations of different ethnic background. In fact, we fully ex-
pect the spectrum of gene-gene interactions to shift from population to population as
genetic architecture changes due to different genetic backgrounds and local ecologies.
We also expect statistical measures of interaction to change as allele frequencies
change. These factors represent significant challenges to detecting and characterizing
gene-gene interactions. This study partly addresses some of these concerns by focusing
on the aggregation of statistical results at the pathway level thus taking the focus off in-
ferential statistical analysis at the SNP level.
It is also important to note that the use of a more liberal significance threshold to im-
prove power means that there is a higher type I error rate that could lead to more
false-positives. This should also be taken into consideration before deciding to carry
out a confirmatory study.
The results of this study support the idea that a bioinformatics approach to GWAS
analysis of bladder cancer yields novel, replicable results not discovered using univari-
ate statistical methods. As we exhaust efforts to identify and list SNPs that have univer-
sal main effects on disease risk across genetic backgrounds and local ecologies, it will
be important explore alternative bioinformatics methods that are designed to embrace
a complex genetic architecture underlying most common diseases such as cancer. This
means we need methods that are able to capture genetic effects that are dependent on
genetic background, environmental context, or that might be based on genetic variants
that segregate only in a small number of families giving rise to locus heterogeneity.
This study is one of the first to measure gene-gene interactions on a genome-wide scale
and to measure their aggregation across biochemical pathways and functional group-
ings of genes as detailed in GO. The carboxy-lysase activity pathway revealed by this
approach was identified across two different GWAS data sets and raises the question as
to whether decarboxylase genes should be investigated as drug targets. These results
are preliminary and warrant confirmatory studies.
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